Journal
FRONTIERS IN PHARMACOLOGY
Volume 12, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2021.786700
Keywords
glioblastoma; blood-brain barrier; nanotherapeutics; drug delivery; nanocarriers
Categories
Funding
- National Key Research and Development Program of China [2019YFA0903801]
- National Natural Science Foundation of China [52073015, 52003021]
- Fundamental Research Funds for the Central Universities [ZY2006]
Ask authors/readers for more resources
Glioblastoma (GBM) is a common malignant primary brain tumor with a poor prognosis. The current standard treatment regimen has limited efficacy, and new therapeutic approaches, such as nanotechnologies for overcoming the blood-brain barrier, hold promise for treating GBM.
Glioblastoma (GBM) is the most common malignant primary brain tumor with a poor prognosis. The current standard treatment regimen represented by temozolomide/radiotherapy has an average survival time of 14.6 months, while the 5-year survival rate is still less than 5%. New therapeutics are still highly needed to improve the therapeutic outcome of GBM treatment. The blood-brain barrier (BBB) is the main barrier that prevents therapeutic drugs from reaching the brain. Nanotechnologies that enable drug delivery across the BBB hold great promise for the treatment of GBM. This review summarizes various drug delivery systems used to treat glioma and focuses on their approaches for overcoming the BBB to enhance the accumulation of small molecules, protein and gene drugs, etc. in the brain.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available